AIM Latest Press Releases

-- November 5, 2026 --

AIM ImmunoTech Highlights Ampligen Opportunity to Potentially Extend Benefits of RAS-Targeted Therapies in Pancreatic Cancer Globe Newswire 9:13 AM

-- October 7, 2026 --

AIM ImmunoTech's Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays Globe Newswire 9:14 AM

-- October 5, 2026 --

AIM ImmunoTech Highlights Recent Media Coverage of Ampligen's Broad-Spectrum Antiviral and Biodefense Potential Globe Newswire 9:22 AM

-- October 1, 2026 --

AIM ImmunoTech Spotlights Growing Attention Around Ampligen Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data Globe Newswire 9:02 AM

-- September 30, 2026 --

AIM ImmunoTech Discusses Ampligen's Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video Globe Newswire 8:44 AM

-- September 22, 2026 --

AIM ImmunoTech Highlights Ampligen's Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines' Daraxonrasib Globe Newswire 8:55 AM

-- September 9, 2026 --

AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen in Pancreatic Cancer in New CEO Corner Video Globe Newswire 9:03 AM

-- September 2, 2026 --

AIM ImmunoTech Significantly Expands Ampligen Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041 Globe Newswire 8:43 AM

-- August 31, 2026 --

AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen) Used in Combination with Pembrolizumab (Keytruda), Expanding Oncology IP Protection for Ampligen Through 2039 Globe Newswire 8:51 AM

-- August 27, 2026 --

JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs ACCESS Newswire 9:01 AM

AIM ImmunoTech Participates in the Virtual Investor 'Why Now' On-Demand Conference Globe Newswire 9:01 AM

-- August 12, 2026 --

AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published 'Breaking Defense' Article Globe Newswire 8:44 AM

-- August 10, 2026 --

AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen Toward Planned Phase 3 Development in Pancreatic Cancer Globe Newswire 8:36 AM

-- August 3, 2026 --

AIM ImmunoTech Ahead of Schedule on 'Last Dose' DURIPANC Critical Clinical Inflection Point Globe Newswire 8:33 AM

-- July 7, 2026 --

AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program Globe Newswire 9:03 AM

-- June 24, 2026 --

AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones Globe Newswire 8:29 AM

-- June 22, 2026 --

AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series Globe Newswire 8:45 AM

-- June 18, 2026 --

AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer Globe Newswire 9:01 AM

-- June 15, 2026 --

AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency Globe Newswire 8:01 AM

-- June 9, 2026 --

AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules Globe Newswire 9:29 AM

-- June 8, 2026 --

AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer Globe Newswire 8:33 AM

Market Data Delayed 15 Minutes